engleski

THE LEVEL OF GASTRIN IN PATIENTS WITH DIABETIC GASTROPARESIS TREATED WITH CISAPRIDE

The aim of the study was to examine the effect of cisapride on the level of gastrin in the serum of patients with diabetic gastroparesis. The study included two groups, each consisting of 20 patients with insulin dependent diabetes mellitus and diabetic gastroparesis. The fasting and postprandial level of gastrin in serum was determined, both at the beginning and at the end of a thirty-day treatment. Gastrin was determined by the RIA method and expressed as SEM&#177; SD (normal <60 pg/ml). Group A patients received 10 mg cisapride tablets three times per day, and group B patients received placebo following the same pattern of administration. In group A, fasting gastrin level was 138.1&#177; 89.1 pg/ml before the treatment, and 98.3&#177; 55.0 pg/ml after the treatment, which was a significant decrease (p<0.05). In group A, postprandial gastrin level was 240.6&#177; 116.3 pg/ml before the treatment, and 170.1&#177; 111.6 pg/ml after the treatment, which was a statistically significant decrease (p<0.05). In group B, fasting gastrin level was 121.4&#177; 66.2 and 121.9&#177; 51.1 pg/ml before and after the treatment, respectively (NS). In group B, postprandial gastrin level was 150.7&#177; 70.6 pg/ml before the treatment and 181.0&#177; 87.9 pg/ml after the treatment. Cisapride treatment decreased the secretion of gastrin in patients with diabetic gastroparesis. Cisapride increased acetylcholine secretion and inhibited gastrin secretion, probably by increasing the level of calcium.

cisapride; gastrin; diabetic gastroparesis

nije evidentirano